

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.**

**百奥赛图(北京)医药科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2315)**

### **DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, 28 August 2024, for the purpose of, among other matters, (i) considering and approving the interim results of the Company and its subsidiaries for the six months ended 30 June 2024 and its publication, and (ii) considering the payment of an interim dividend, if any.

By order of the Board  
**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**  
**Shen Yuelei**  
*Chairman of the Board, Chief Executive Officer and  
Executive Director*

Hong Kong, 16 August 2024

*As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.*